The decision to actively pursue the hepatocellular carcinoma (primary liver cancer) indication comes after a detailed clinical and regulatory review led by new OncoSil CEO Daniel Kenny. OncoSil™ is an implantable device that emits radiation directly into a specific targeted tumour, and delivers radiation therapy locally for up to three months.
The decision to actively pursue the hepatocellular carcinoma...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.050(4.42%) |
Mkt cap ! $20.33M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.15 | $1.08 | $45.62K | 40.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 718 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 2361 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |